Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.40 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 5/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.38 |
| ▸ | RXRA | P19793 | 3/20 | 0.38 |
| ▸ | PPARD | Q03181 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21945003 | 0.91 | SRD5A2 (0.47) | SRD5A2SRD5A1HSD17B1HSD17B2MAOB | |
| SCHEMBL18002480 | 0.83 | SRD5A2 (0.52) | SRD5A2NR4A2SRD5A1MAOBNR1H2 | |
| SCHEMBL21944881 | 0.80 | PPARD (0.46) | NR4A2MAOBPPARDPPARAMRGPRX4 | |
| SCHEMBL18005377 | 0.76 | SRD5A2 (0.42) | SRD5A2NR4A2SRD5A1MAOBNR1H2 | |
| SCHEMBL18002342 | 0.74 | SRD5A2 (0.45) | SRD5A2SRD5A1HSD17B1HSD17B2MAOB | |
| SCHEMBL6242376 | 0.74 | SRD5A2 (0.71) | SRD5A2NR4A2SRD5A1MAOBNR1H2 | |
| SCHEMBL12577906 | 0.72 | SRD5A2 (0.62) | SRD5A2SRD5A1MAOBMAOA | |
| SCHEMBL12335444 | 0.72 | SRD5A2 (0.65) | SRD5A2SRD5A1MAOBMAOA | |
| SCHEMBL6242372 | 0.72 | SRD5A2 (0.68) | SRD5A2NR1H2NR1H3RXRAPPARD | |
| SCHEMBL21944798 | 0.71 | NR4A2 (0.45) | NR4A2MAOBMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | SRD5A2 937/4885NR4A2 2048/4885SRD5A1 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.